Press Release: Neuromed Pharmaceuticals Licenses Phase 3 Chronic Pain Product from ALZA Corporation (JNJ) - FierceBiotech

"Neuromed Pharmaceuticals Licenses Phase 3 Chronic Pain Product from ALZA Corporation (JNJ); Neuromed to Make Upfront Payment of $30 Million"